



# Contents

*Preface*

*v*

|                                                                |              |
|----------------------------------------------------------------|--------------|
| <b>1. Introduction to Medicinal Chemistry</b>                  | <b>1–4</b>   |
| 1.1 Introduction                                               | 1            |
| 1.2 Drug Design                                                | 3            |
| 1.2.1 Discovery and Research                                   | 3            |
| 1.2.2 Drug Development                                         | 3            |
| 1.2.3 Regulatory Review and Approval                           | 4            |
| 1.2.4 Marketing                                                | 4            |
| <b>2. General Principle of Drug Action</b>                     | <b>5–11</b>  |
| 1. Introduction                                                | 5            |
| 2. Absorption of Drug                                          | 5            |
| 3. Distribution of Drug                                        | 9            |
| 4. Protein Binding                                             | 10           |
| 4.1 Tissue Depots                                              | 10           |
| 5. Metabolism and Excretion                                    | 11           |
| <b>3. Receptors</b>                                            | <b>12–32</b> |
| 1. Introduction                                                | 12           |
| 2. Drug – Receptor Interaction                                 | 14           |
| 3. Drug – Receptor Bonds                                       | 16           |
| 3.1 Covalent Bond                                              | 16           |
| 3.2 Ionic Bond                                                 | 16           |
| 3.3 Hydrogen Bond                                              | 17           |
| 3.4 Hydrophobic Interaction                                    | 17           |
| 3.5 Van der Waals (or) London forces                           | 18           |
| 3.6 Charge Transfer Complexes                                  | 18           |
| 4. Theories of Receptor                                        | 18           |
| 4.1 Occupation Theory                                          | 18           |
| 4.2 Rate Theory                                                | 20           |
| 4.3 The Induced – Fit Theory of Enzyme — Substrate Interaction | 21           |
| 4.4 Macromolecular Perturbation Theory                         | 21           |
| 4.5 Activation – Aggregation Theory                            | 22           |
| 4.6 Two State Receptor Model                                   | 23           |

|                                                                         |               |
|-------------------------------------------------------------------------|---------------|
| 5. Types of Receptors                                                   | 23            |
| 5.1 Channel Linked Receptor or Ligand – Gated ion Channel Receptors     | 23            |
| 5.2 G - Protein Coupled Receptors                                       | 24            |
| 5.3 Membrane Bound Enzyme Receptors                                     | 28            |
| 5.4 Nuclear Receptor or Intracellular Receptor                          | 31            |
| 5.5 Summary of Receptor Types                                           | 32            |
| <b>4. Physicochemical Parameters in Relation to Biological Activity</b> | <b>33–63</b>  |
| 1. Introduction                                                         | 33            |
| 2. Physical Properties                                                  | 33            |
| 2.1 Solubility                                                          | 33            |
| 2.2 Partition co-efficient                                              | 37            |
| 2.3 Ionization and $pK_a$ value                                         | 38            |
| 2.4 Hydrogen-Bonding                                                    | 42            |
| 2.5 Surface Activity                                                    | 44            |
| 2.6 Complexation                                                        | 45            |
| 2.7 Redox Potential                                                     | 45            |
| 3. Steric Features of Drug                                              | 48            |
| 3.1 Conformational Isomers                                              | 49            |
| 3.2 Optical Isomers                                                     | 51            |
| 4. Bioisosterism                                                        | 54            |
| 4.1 Classical Bioisosteres                                              | 55            |
| 4.2 Non-classical Bioisosteres                                          | 59            |
| <b>5. Drug Metabolism</b>                                               | <b>64–110</b> |
| 1. Introduction                                                         | 64            |
| 1.1 Sites of Bio-transformation                                         | 64            |
| 1.2 Pathways of Drug Metabolism                                         | 65            |
| 1.3 General Summary of Phase I and Phase II Metabolic Pathway           | 66            |
| 1.4 Enzymes Involved in Drug Metabolism                                 | 67            |
| 2. Phase I Reactions                                                    | 70            |
| 2.1 Oxidative Reactions                                                 | 70            |
| 2.1.1 Oxidation of Aromatic Carbon Atom                                 | 72            |
| 2.1.2 Oxidation of Olefins                                              | 75            |
| 2.1.3 Oxidation at Benzylic Carbon                                      | 76            |
| 2.1.4 Oxidation of Allylic Carbon                                       | 77            |
| 2.1.5 Oxidation of Carbon atom to Carbonyl and Imines                   | 78            |
| 2.1.6 Oxidation of Aliphatic Carbon atom (Aliphatic hydroxylation)      | 79            |
| 2.1.7 Oxidation of Alicyclic Carbon atom                                | 79            |
| 2.1.8 Oxidation of Carbon-Hetero atoms                                  | 80            |

|                                                 |                |
|-------------------------------------------------|----------------|
| 2.1.9 Oxidation Involving C-N system            | 80             |
| 2.1.10 Oxidation of Carbon-Sulfur System        | 85             |
| 2.1.11 Oxidation Involving Carbon-Oxygen System | 87             |
| 2.1.12 Other Oxidative Bio-transformation       | 88             |
| 2.2 Reduction Reactions                         | 89             |
| 2.2.1 Reduction of Aldehyde and Ketone          | 89             |
| 2.2.2 Reduction of Azo and Nitro Compound       | 90             |
| 2.3 Hydrolytic Reactions                        | 90             |
| 2.3.1 Hydrolysis of Esters and Amides           | 90             |
| 2.3.2 Hydrolysis of Amide                       | 91             |
| 3. Phase II (or) Conjugation Reactions          | 92             |
| 3.1 Glucuronic acid Conjugation                 | 92             |
| 3.2 Sulfate Conjugation                         | 95             |
| 3.3 Conjugation with $\alpha$ -amino acids      | 97             |
| 3.4 Conjugation with Glutathione                | 98             |
| 3.5 Acetyl conjugation                          | 101            |
| 3.6 Methylation                                 | 103            |
| 4. Factors Affecting Drug Metabolism            | 105            |
| <b>6. Prodrugs</b>                              | <b>111–135</b> |
| 1. Introduction                                 | 111            |
| 2. Prodrug strategy in Drug Design              | 112            |
| 3. Ideal Requirements of Prodrug                | 114            |
| 4. Types of Prodrugs                            | 114            |
| 4.1 Carrier Linked Prodrug                      | 114            |
| 4.2 Bio-precursor Prodrug                       | 120            |
| 5. Applications of Prodrug                      | 121            |
| 5.1 Pharmaceutical Applications                 | 121            |
| 5.2 Pharmacological Applications                | 125            |
| <b>7. General Anaesthetics</b>                  | <b>136–148</b> |
| 1. Introduction                                 | 136            |
| 2. Mechanism of Action                          | 136            |
| 3. Classification                               | 137            |
| 3.1 Inhalation Anaesthetics                     | 138            |
| 3.2 Intravenous Anaesthetics                    | 144            |
| <b>8. Local Anaesthetics</b>                    | <b>149–170</b> |
| 1. Introduction                                 | 149            |
| 2. Mechanism of Action                          | 149            |

|                                          |                |
|------------------------------------------|----------------|
| 3. Structure Activity Relationship       | 150            |
| 4. Classification                        | 152            |
| 4.1 Ester based                          | 153            |
| 4.2 Amide based                          | 161            |
| 4.3 Amino Ether derivatives              | 166            |
| 4.4 Amino Ketone derivatives             | 168            |
| 4.5 Alcohol derivatives                  | 168            |
| 4.6 Miscellaneous                        | 169            |
| <b>9. Sedative and Hypnotics</b>         | <b>171–206</b> |
| 1. Introduction                          | 171            |
| 2. Classification                        | 171            |
| 2.1 Barbiturates                         | 173            |
| 2.2 Benzodiazepines                      | 186            |
| 2.3 Triazolo-1, 4 - Benzodiazepines      | 197            |
| 2.4 Pyrazolo Pyrimidine                  | 199            |
| 2.5 Imidazopyridine                      | 199            |
| 2.6 Cyclopyrrolone derivative            | 200            |
| 2.7 Piperidinedione derivatives          | 200            |
| 2.8 Disubstituted Quinazolone derivative | 202            |
| 2.9 Carbamic acid Ester of Glycol        | 202            |
| 2.10 Carbamic acid Ester of Alcohol      | 203            |
| 2.11 Chloral derivatives                 | 204            |
| 2.12 Acetylenic Alcohol                  | 204            |
| 2.13 Cyclic Ether                        | 205            |
| 2.14 Piperazine derivative               | 205            |
| 2.15 Miscellaneous                       | 206            |
| <b>10. Anticonvulsants</b>               | <b>207–222</b> |
| 1. Introduction                          | 207            |
| 2. Classification                        | 209            |
| 2.1 Barbiturates                         | 210            |
| 2.2 Hydantoins                           | 211            |
| 2.3 Oxazolidinediones                    | 213            |
| 2.4 Succinimides                         | 215            |
| 2.5 Imino stilbenes                      | 217            |
| 2.6 Benzodiazepines                      | 218            |
| 2.7 Newer Antiepileptics                 | 220            |
| 2.8 Miscellaneous                        | 221            |

|                                                                      |                |
|----------------------------------------------------------------------|----------------|
| <b>11. Central Nervous System Stimulant</b>                          | <b>223–268</b> |
| 1. Introduction                                                      | 223            |
| 2. Analeptics                                                        | 224            |
| 2.1 Introduction                                                     | 224            |
| 3. Methyl Xanthines                                                  | 226            |
| 3.1 Introduction                                                     | 226            |
| 3.2 Mechanism of Action                                              | 227            |
| 4. Psychomotor Stimulants                                            | 233            |
| 4.1 Introduction                                                     | 233            |
| 4.2 Cocaine                                                          | 233            |
| 4.3 Central Sympathomimetic Analeptics                               | 234            |
| 5. Antidepressant                                                    | 242            |
| 5.1 Introduction                                                     | 242            |
| 5.2 Classification                                                   | 243            |
| 5.2.1 Mono Amine Oxidase Inhibitors (MAOIs)                          | 243            |
| 5.2.2 Tricyclic Antidepressant                                       | 247            |
| 5.2.3 Selective Serotonin Reuptake Inhibitors (SSRIs)                | 256            |
| 5.2.4 Selective Norepinephrine Reuptake Inhibitors (SNRI)            | 259            |
| 5.2.5 Dual Serotonin and Norepinephrine Reuptake Inhibitor (SNRI)    | 260            |
| 5.2.6 Norepinephrine and Dopamine Reuptake Inhibitor (NDRI)          | 261            |
| 5.2.7 Alpha-2 Antagonist plus Serotonin-2 and Serotonin-3 Antagonist | 261            |
| 5.2.8 Serotonin-2-antagonist and Reuptake Inhibitors (SARIs)         | 262            |
| 5.2.9 Serotonin Reuptake Enhancer                                    | 263            |
| 6. Psychotomimetic Drugs [Hallucinogenic Drug]                       | 264            |
| 6.1 Introduction                                                     | 264            |
| 6.2 Classification                                                   | 264            |
| 6.2.1 Aryl Amino Hallucinogens                                       | 265            |
| 6.2.2 Dissociate agents                                              | 267            |
| 6.2.3 Euphorian – Stimulant                                          | 267            |
| 6.2.4 Depressant – Intoxicant                                        | 267            |
| <b>12. Tranquilizers</b>                                             | <b>269–286</b> |
| 1. Introduction                                                      | 269            |
| 2. Classification                                                    | 269            |
| 2.1 Phenothiazines                                                   | 270            |
| 2.2 Benzodiazepines                                                  | 279            |
| 2.3 Fluoro Butyrophenones                                            | 280            |

|                                                                       |                |
|-----------------------------------------------------------------------|----------------|
| 2.4 Thioxanthenes                                                     | 283            |
| 2.5 Dibenzoxazepines                                                  | 285            |
| 2.6 Benzisoxazole                                                     | 286            |
| <b>13. Antihistamines</b>                                             | <b>287–326</b> |
| 1. Introduction                                                       | 287            |
| 2. Histamine Release Inhibitors — Mast Cell Stabilizers               | 289            |
| 2.1 Introduction                                                      | 289            |
| 3. Released Histamine Inhibitors ( $H_1$ Antagonist - Antihistamines) | 291            |
| 3.1 Introduction                                                      | 291            |
| 3.2 Mechanism of Action of Antihistamines                             | 291            |
| 3.3 Structure Activity Relationship                                   | 291            |
| 3.4 Therapeutic Applications of Antihistamines                        | 293            |
| 3.5 Classification                                                    | 293            |
| 3.5.1 First Generation $H_1$ Antagonists                              | 294            |
| 3.5.2 Second Generation Antihistamines                                | 315            |
| 3.5.3 Topical Antihistamines                                          | 319            |
| 4. Anti-Secretory Drugs                                               | 320            |
| 4.1 Introduction                                                      | 320            |
| 4.2 Classification of Antiulcer Drugs                                 | 320            |
| 4.2.1 $H_2$ - Receptor Antagonist                                     | 320            |
| 4.2.2 Proton Pump Inhibitors                                          | 324            |
| <b>14. Diuretics</b>                                                  | <b>327–359</b> |
| 1. Introduction                                                       | 327            |
| 2. Classification                                                     | 333            |
| 2.1 Mercurial Diuretics                                               | 334            |
| 2.2 Non-mercurial Diuretics                                           | 336            |
| 2.2.1 Thiazide and Hydrothiazide Diuretics                            | 336            |
| 2.2.2 <i>Carbonic Anhydrase</i> Inhibitors                            | 345            |
| 2.2.3 Sulphonamide Diuretics                                          | 350            |
| 2.2.4 Aldosterone Antagonists                                         | 352            |
| 2.2.5 High Ceiling or Loop Diuretics                                  | 353            |
| 2.2.6 Methyl xanthines                                                | 357            |
| 2.2.7 Pyrazinoyl Guanidine                                            | 357            |
| 2.2.8 Osmotic Diuretics                                               | 358            |
| 2.2.9 Miscellaneous                                                   | 359            |

|                                                        |                |
|--------------------------------------------------------|----------------|
| <b>15. Analgesics, Antipyretics and Antirheumatics</b> | <b>360–377</b> |
| 1. Introduction                                        | 360            |
| 2. Classification                                      | 360            |
| 2.1 Aniline and p-Aminophenol Analogues                | 361            |
| 2.2 Salicylic acid Analogues                           | 363            |
| 2.3 Quinoline derivatives                              | 367            |
| 2.4 Pyrazolones and Pyrazolidinones                    | 368            |
| 2.5 N - Arylanthranilic acid derivatives               | 373            |
| 3. Anti-Rheumatic Agents                               | 375            |
| 3.1 Introduction                                       | 375            |
| 3.2 Classification                                     | 375            |
| <b>16. Narcotic Analgesics</b>                         | <b>376–408</b> |
| 1. Introduction                                        | 376            |
| 2. Classification                                      | 379            |
| 2.1 Morphine and its Related Compounds                 | 379            |
| 2.2 Morphinan Analogues                                | 393            |
| 2.3 Morphan Analogues                                  | 395            |
| 2.4 4 - Phenyl Piperidine Analogues                    | 396            |
| 2.5 Phenyl propylamine Analogues                       | 400            |
| 2.6 Miscellaneous                                      | 401            |
| 3. Narcotic Antagonists                                | 402            |
| 4. Antitussives                                        | 405            |
| 4.1 Introduction                                       | 405            |
| 4.1.1 Centrally acting Antitussives                    | 405            |
| 4.1.2 Peripherally acting Antitussives                 | 405            |
| <b>17. Non-Steroidal Anti-Inflammatory Drugs</b>       | <b>409–425</b> |
| 1. Introduction                                        | 409            |
| 2. Mechanism of Action                                 | 409            |
| 3. Structure Activity Relationship                     | 411            |
| 4. Classification                                      | 412            |
| 4.1 Heteroaryl acetic acid Analogues                   | 413            |
| 4.2 Aryl acetic acid Analogues                         | 416            |
| 4.3 Aryl Propionic acid Analogues                      | 419            |
| 4.4 Oxicams                                            | 422            |
| 4.5 Selective COX-2 Inhibitors                         | 423            |

|                                                    |                |
|----------------------------------------------------|----------------|
| <b>18. Cholinergic and Anticholinergic Drugs</b>   | <b>426–469</b> |
| 1. Introduction                                    | 426            |
| 1.1 Neurochemistry                                 | 427            |
| 1.2 Acetylcholine                                  | 428            |
| 1.2.1 Stereochemistry of Acetylcholine             | 428            |
| 1.2.2 Acetylcholine Receptors                      | 429            |
| 2. Cholinomimetic (or) Parasympathomimetic Agents  | 433            |
| 2.1 Introduction                                   | 433            |
| 2.2 Classification                                 | 434            |
| 2.2.1 Direct acting Cholinergic Drugs              | 434            |
| 2.2.2 Indirect acting Cholinergic Agonist          | 439            |
| 3. Cholinergic Blocking Agents (or) Antispasmodics | 447            |
| 3.1 Introduction                                   | 447            |
| 3.2 Structure Activity Relationship                | 447            |
| 3.3 Therapeutic Uses                               | 448            |
| 3.4 Parasympathetic Postganglionic Blocking Agents | 449            |
| 3.4.1 Classification                               | 449            |
| 3.4.1.1 Solanaceous Alkaloids                      | 449            |
| 3.4.1.2 Synthetic Cholinergic Blocking Agents      | 453            |
| 4. Ganglionic Blocking Agents                      | 462            |
| 4.1 Introduction                                   | 462            |
| 4.2 Classification                                 | 462            |
| 5. Neuromuscular Blocking agent                    | 465            |
| 5.1 Natural Compounds                              | 465            |
| 5.2 Synthetic Compounds                            | 467            |
| <b>19. Adrenergic Drugs</b>                        | <b>470–516</b> |
| 1. Introduction                                    | 470            |
| 1.1 Adrenergic Nerve Transmission                  | 470            |
| 1.2 Biosynthesis                                   | 471            |
| 1.3 Metabolism and Distribution of Catecholamines  | 473            |
| 1.4 Adrenergic Receptors                           | 474            |
| 1.5 Clinical uses of Adrenergic Agents             | 476            |
| 2. Sympathomimetic Agents                          | 476            |
| 2.1 Introduction                                   | 476            |
| 2.2 Structure Activity Relationship                | 477            |

|                                                                      |                |
|----------------------------------------------------------------------|----------------|
| 2.3 Classification of Adrenergic Agonists                            | 479            |
| 2.3.1 Direct-Acting Sympathomimetics (Agonists)                      | 480            |
| 2.3.1.1 Endogenous Catecholamines                                    | 480            |
| 2.3.1.2 $\alpha$ - Adrenergic Receptor Agonist                       | 483            |
| 2.3.1.3 $\beta$ - Adrenergic Receptor Agonist                        | 490            |
| 2.3.1.4 Dual $\alpha$ and $\beta$ - Adrenergic Receptor Agonist      | 495            |
| 2.3.2 Indirect - Acting Sympathomimetics                             | 496            |
| 2.3.3 Sympathomimetic with Mixed Mechanism of Action                 | 498            |
| 3. Sympatholytic (or) Adreno Receptor Blocking Agents                | 500            |
| 3.1 $\alpha$ - Adrenergic Blocking Agents                            | 500            |
| 3.1.1 Ergot Alkaloids                                                | 500            |
| 3.1.2 Quinazolines                                                   | 501            |
| 3.1.3 Imidazolines                                                   | 505            |
| 3.1.4 $\beta$ - Halo alkyl amines                                    | 506            |
| 4. $\beta$ - Adrenergic Blocking Agents                              | 508            |
| 4.1 Introduction                                                     | 508            |
| 4.2 Structure Activity Relationship                                  | 508            |
| 4.3 Classification                                                   | 509            |
| 4.3.1 Aryloxy Propyl Amines                                          | 510            |
| 4.3.2 Aryl Ethanol Amine derivative                                  | 515            |
| 5. $\beta$ - Blockers with $\alpha_1$ - Receptor Antagonist Activity | 515            |
| <b>20. Prostaglandins</b>                                            | <b>517–538</b> |
| 1. Introduction                                                      | 517            |
| 2. Nomenclature                                                      | 518            |
| 2.1 Nature of Cyclopentane Ring                                      | 519            |
| 2.2 Nature of the Side Chain                                         | 520            |
| 3. Biosynthesis                                                      | 521            |
| 3.1 Cyclooxygenase pathway                                           | 521            |
| 3.2 Lipoxygenase pathway                                             | 523            |
| 4. Pharmacological Activities                                        | 525            |
| 5. Structure Activity Relationship                                   | 531            |
| 6. Eicosanoids Approved for Clinical Use                             | 534            |
| 7. Prostaglandins for Ophthalmic Use                                 | 536            |
| <i>Index</i>                                                         | <i>539–546</i> |